The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
Open Access
- 23 February 2023
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 27 (3) , 271-276
Abstract
Background: Lichen Planus (LP) is a dermatological disorder characterized by violaceous papules that affect the cutaneous region, nails, scalp, and mucous membranes. Current molecular and clinical studies point to the Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathway as a potential effector of LP pathology. Objective: This systematic review summarizes the current reported literature outcomes for patients receiving JAK inhibitors to treat LP. Methods: MEDLINE and Embase were searched on 16 October, 2022, and 15 original articles were included, with 56 LP patients. Results: (mean age: 54.5 years, range: 26-81 years, male: 26.8%). The treatment outcomes were included for the following JAK inhibitors: tofacitinib ( n = 30), baricitinib ( n = 16), ruxolitinib ( n = 12), and upadacitinib ( n = 2). Patient outcomes were classified into complete resolution, partial resolution, and no resolution. Patients achieving complete resolution represented 25% ( n = 4/16) in the baricitinib group, 10% ( n = 3/30) in the tofacitinib group, 16.7% ( n = 2/12) in the ruxolitinib group, and 100% (2/2) in the upadacitinib group. Partial resolution patients represented 31.3% ( n = 5/16) of baricitinib patients, 60% ( n = 18/30) of tofacitinib patients, and 83% ( n = 10/12) of ruxolitinib patients. 43.8% ( n = 7/16) of baricitinib patients and 10% ( n = 9/30) of tofacitinib patients had no resolution of lesions. Conclusion: This review also highlights the significance of utilizing a uniform outcome measure for LP, as it aids in reporting more generalizable results, reduces reporting bias, and ultimately lead to improved clinical outcomes for LP patients.Keywords
This publication has 17 references indexed in Scilit:
- Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in PsoriasisJournal of Immunology Research, 2018
- Lichen PlanusNew England Journal of Medicine, 2012
- Hydroxychloroquine and lichen planopilaris: Efficacy and introduction of Lichen Planopilaris Activity Index scoring systemJournal of the American Academy of Dermatology, 2010
- Th1/Th2 Cytokine Ratio in Tissue Transudates from Patients with Oral Lichen PlanusMediators of Inflammation, 2007
- Type I interferon‐associated cytotoxic inflammation in lichen planusJournal of Cutaneous Pathology, 2006
- Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular DiseaseAnnals of Internal Medicine, 2004
- Interferon-γ: an overview of signals, mechanisms and functionsJournal of Leukocyte Biology, 2003
- Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammationThe Journal of Pathology, 2001
- Lichen planusJournal of the American Academy of Dermatology, 1991
- Treatment of lichen planus with acitretinJournal of the American Academy of Dermatology, 1991